TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))

Docket No. DI-5774

In Re Application Of: Connell et al.

Serial No.

Filing Date

Examiner

Group Art Unit

10/074,532

February 11, 2002

Unknown

3763

IS CONNECTOR AND CAP HAVING AN INTEGRAL DISINFECTANT

Address to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 TECHNOLOGY CENTER R3700

37 CFR 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2.	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37
	CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a
	Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that
	otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

	OSURE STATEMENT 7(c))	Docket No. DI-5774					
In Re Application: Connell et al.							
Serial No.	Filing Date	Examiner	Group Art Unit				
10/074,532	February 11, 2002	Unknown	3763				
DIALYSIS CONNECTOR AND CAP HAVING AN INTEGRAL DISINFECTANT							
ATENT & THE		ment of Fee ects to pay the fee set forth in 37 CFR 1.	17(1) RECEIVED				
□ A check in the amount of is attached. □ The Director is hereby authorized to charge and credit Deposit Account No. □ Charge the amount of □ Credit any overpayment. □ Charge any additional fee required. □ Certificate of Transmission by Facsimile* □ Certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: □ Signature □ Charge the amount of □ Credit any overpayment. □ Certificate of Mailing by First Class Mail □ Certify that this document and fee is being deposited on 10-02-2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. □ Signature Signature of Person Mailing Correspondence							
Typed or Printed N	Name of Person Signing Certificate	Renee Street Typed or Printed Name of Pers	on Mailing Certificate				
*This certificate may only be used if paying by deposit account. Signature Robert M. Barrett Reg. No. 30,142 BELL, BOYD & LLOYD LLC P.O. Box 1135 Chicago, IL 60690-1135 Phone: 312-807-4204							
CC:							

TRANSMITTAL OI	Docket No. DI-5774							
In Re Application Of: Connell et al.								
Serial No.	Filing Date	Examiner	Group Art Unit					
10/074,532	February 11, 2002	Unknown	3763					
THE DIALYSIS CONNECTOR AND CAP HAVING AN INTEGRAL DISINFECTANT								
DET 0 6 2000			RECEIVED					
Arms Re	A	ddress to:	OCT 0 9 2003					
WEST & VI	Commiss P.O		ECHNOLOGY CENTER R3700					
37 CFR 1.97(b)								
1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c)								
2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:								
☐ the statement specified in 37 CFR 1.97(e);								
OR								
the fee set forth in 37 CFR 1.17(p).								
·								